BZPEERReading, trust and collaboration for research
Menu

Discover

GraphFollow connections around a paper, topic or saved view.

Workspaces

HomePick up where your research flow left off.InboxHandle requests, replies and notifications from one place.CollectionsCurate reading lists, evidence sets and shareable dossiers.ResearchSee your private provenance graph, trail and imports.CollaborationMove from discovery into focused discussion rooms.PublishDraft, preview and publish full-text research articles.

Network

ExpertsFind specialists worth following or asking for help.CommunitiesJoin research circles organized around shared work.PartnersSee external organizations active around the same topics.

Opportunities

ListingsBrowse roles, calls and collaborations with clearer fit signals.

Account

Log inReturn to your reading and collaboration workspace.Create accountStart saving work, following people and joining teams.
Log inCreate account

Researcher profile

Thomas Brettin

Thomas Brettin contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate
Quantitative MethodsMachine LearningArtificial IntelligenceComputer Visioneess.IVMultiagent SystemsRobotics

Trust snapshot

Quick read

Trust 17 - UnverifiedVerification L1Unclaimed author
4works
0followers
7topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

4 published item(s)

preprint2026arXiv

PRISM: Protocol Refinement through Intelligent Simulation Modeling

Automating experimental protocol design and execution remains as a fundamental bottleneck in realizing self-driving laboratories. We introduce PRISM (Protocol Refinement through Intelligent Simulation Modeling), a framework that automates the design, validation, and execution of experimental protocols on a laboratory platform composed of off-the-shelf robotic instruments. PRISM uses a set of language-model-based agents that work together to generate and refine experimental steps. The process begins with automatically gathering relevant procedures from web-based sources describing experimental workflows. These are converted into structured experimental steps (e.g., liquid handling steps, deck layout and other related operations) through a planning, critique, and validation loop. The finalized steps are translated into the Argonne MADSci protocol format, which provides a unified interface for coordinating multiple robotic instruments (Opentrons OT-2 liquid handler, PF400 arm, Azenta plate sealer and peeler) without requiring human intervention between steps. To evaluate protocol-generation performance, we benchmarked both single reasoning models and multi-agent workflow across constrained and open-ended prompting paradigms. The resulting protocols were validated in a digital-twin environment built in NVIDIA Omniverse to detect physical or sequencing errors before execution. Using Luna qPCR amplification and Cell Painting as case studies, we demonstrate PRISM as a practical end-to-end workflow that bridges language-based protocol generation, simulation-based validation, and automated robotic execution.

0 citations0 reviewsNo code linkedOpen access
preprint2022arXiv

Data augmentation and multimodal learning for predicting drug response in patient-derived xenografts from gene expressions and histology images

Patient-derived xenografts (PDXs) are an appealing platform for preclinical drug studies because the in vivo environment of PDXs helps preserve tumor heterogeneity and usually better mimics drug response of patients with cancer compared to CCLs. We investigate multimodal neural network (MM-Net) and data augmentation for drug response prediction in PDXs. The MM-Net learns to predict response using drug descriptors, gene expressions (GE), and histology whole-slide images (WSIs) where the multi-modality refers to the tumor features. We explore whether the integration of WSIs with GE improves predictions as compared with models that use GE alone. We use two methods to address the limited number of response values: 1) homogenize drug representations which allows to combine single-drug and drug-pairs treatments into a single dataset, 2) augment drug-pair samples by switching the order of drug features which doubles the sample size of all drug-pair samples. These methods enable us to combine single-drug and drug-pair treatments, allowing us to train multimodal and unimodal neural networks (NNs) without changing architectures or the dataset. Prediction performance of three unimodal NNs which use GE are compared to assess the contribution of data augmentation methods. NN that uses the full dataset which includes the original and the augmented drug-pair treatments as well as single-drug treatments significantly outperforms NNs that ignore either the augmented drug-pairs or the single-drug treatments. In assessing the contribution of multimodal learning based on the MCC metric, MM-Net statistically significantly outperforms all the baselines. Our results show that data augmentation and integration of histology images with GE can improve prediction performance of drug response in PDXs.

0 citations0 reviewsNo code linkedOpen access
preprint2020arXiv

Deep Medical Image Analysis with Representation Learning and Neuromorphic Computing

We explore three representative lines of research and demonstrate the utility of our methods on a classification benchmark of brain cancer MRI data. First, we present a capsule network that explicitly learns a representation robust to rotation and affine transformation. This model requires less training data and outperforms both the original convolutional baseline and a previous capsule network implementation. Second, we leverage the latest domain adaptation techniques to achieve a new state-of-the-art accuracy. Our experiments show that non-medical images can be used to improve model performance. Finally, we design a spiking neural network trained on the Intel Loihi neuromorphic chip (Fig. 1 shows an inference snapshot). This model consumes much lower power while achieving reasonable accuracy given model reduction. We posit that more research in this direction combining hardware and learning advancements will power future medical imaging (on-device AI, few-shot prediction, adaptive scanning).

0 citations0 reviewsNo code linkedOpen access
preprint2020arXiv

Ensemble Transfer Learning for the Prediction of Anti-Cancer Drug Response

Transfer learning has been shown to be effective in many applications in which training data for the target problem are limited but data for a related (source) problem are abundant. In this paper, we apply transfer learning to the prediction of anti-cancer drug response. Previous transfer learning studies for drug response prediction focused on building models that predict the response of tumor cells to a specific drug treatment. We target the more challenging task of building general prediction models that can make predictions for both new tumor cells and new drugs. We apply the classic transfer learning framework that trains a prediction model on the source dataset and refines it on the target dataset, and extends the framework through ensemble. The ensemble transfer learning pipeline is implemented using LightGBM and two deep neural network (DNN) models with different architectures. Uniquely, we investigate its power for three application settings including drug repurposing, precision oncology, and new drug development, through different data partition schemes in cross-validation. We test the proposed ensemble transfer learning on benchmark in vitro drug screening datasets, taking one dataset as the source domain and another dataset as the target domain. The analysis results demonstrate the benefit of applying ensemble transfer learning for predicting anti-cancer drug response in all three applications with both LightGBM and DNN models. Compared between the different prediction models, a DNN model with two subnetworks for the inputs of tumor features and drug features separately outperforms LightGBM and the other DNN model that concatenates tumor features and drug features for input in the drug repurposing and precision oncology applications. In the more challenging application of new drug development, LightGBM performs better than the other two DNN models.

0 citations0 reviewsNo code linkedOpen access